TrialFrontiers in immunology2022

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.

Wenwu He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.